贝达药业：注射用MCLA-129与盐酸恩沙替尼胶囊联用治疗晚期实体瘤获得药物临床试验批准

Core Viewpoint - The announcement by Beida Pharmaceutical regarding the approval of clinical trials for MCLA-129 in combination with ensartinib represents a significant step in the company's drug development pipeline, although it is noted that this will not have a major impact on the company's recent performance [2]. Group 1: Company Developments - Beida Pharmaceutical has received approval from the NMPA for clinical trials of MCLA-129, a bispecific antibody targeting both EGFR and c-Met, in conjunction with ensartinib, a multi-target inhibitor [2]. - The approval is a positive development for the company, indicating progress in its research and development efforts [2]. - The company must still obtain consent from the ethics committee and the Chinese Human Genetic Resources Management Office, introducing a level of uncertainty in the trial process [2].